← Ardelyx (ARDX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Ardelyx (ARDX)
Pharmaceutical Preparations · market cap $860M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-29 (est.)
Earnings
Pipeline
9
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Ardelyx (ARDX) is a pharmaceutical company with a market cap of ~$1.3B and a diversified pipeline centered on gastrointestinal and renal indications. Its lead commercial asset, Tenapanor, is approved for hyperphosphatemia and IBS-C, but a July 2026 regulatory setback clouds the near-term picture. The company faces a critical liquidity constraint with only ~$31M cash and a ~2.9-month runway, against $172M net debt.
The catalyst path
- 2026-10-29 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · Tenapanorimp 7/10
- 2027-02-26 (est.)Phase 3 · Tenapanor 5 mg BIDimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| RDX013 | Phase 2 | Hyperkalemia |
| RDX5791 | Phase 2 | Constipation Predominant Irritable Bowel Syndrome |
| AZD1722 (in-patient) | Phase 2 | End Stage Renal Disease |
| AZD1722 | Phase 3 | Chronic Kidney Disease |
| Tenapanor 50 MG | Phase 3 | Irritable Bowel Syndrome With Constipation (IBS-C) |
| Sevelamer Carbonate | Phase 3 | Hyperphosphatemia |
| Tenapanor | Phase 3 | Hyperphosphatemia |
| Phosphate Binder Agents | Phase 3 | Hyperphosphatemia |
| Tenapanor 5 mg BID | Phase 3 | Chronic Idiopathic Constipation (CIC) |
Price & technical context
3-month
-35.9%
6-month
-44.7%
12-month
-38.7%
52-wk range
$3.38–$7.99
vs 50-day MA
-15.3%
vs 200-day MA
-40.2%
Realized vol
60.4%
Max drawdown
-57.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ARDX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.